AU4710699A - Bicyclic sPLA2 inhibitors - Google Patents

Bicyclic sPLA2 inhibitors

Info

Publication number
AU4710699A
AU4710699A AU47106/99A AU4710699A AU4710699A AU 4710699 A AU4710699 A AU 4710699A AU 47106/99 A AU47106/99 A AU 47106/99A AU 4710699 A AU4710699 A AU 4710699A AU 4710699 A AU4710699 A AU 4710699A
Authority
AU
Australia
Prior art keywords
bicyclic
spla2 inhibitors
spla2
inhibitors
pyrrolo
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Abandoned
Application number
AU47106/99A
Other languages
English (en)
Inventor
Darrell Robert Hutchison
Michael John Martinelli
Thomas Michael Wilson
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Eli Lilly and Co
Original Assignee
Eli Lilly and Co
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Eli Lilly and Co filed Critical Eli Lilly and Co
Publication of AU4710699A publication Critical patent/AU4710699A/en
Abandoned legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
    • C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
    • C07D487/04—Ortho-condensed systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/06—Antiasthmatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/18—Drugs for disorders of the endocrine system of the parathyroid hormones
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07F—ACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM
    • C07F9/00—Compounds containing elements of Groups 5 or 15 of the Periodic Table
    • C07F9/02—Phosphorus compounds
    • C07F9/547—Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom
    • C07F9/6561—Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom containing systems of two or more relevant hetero rings condensed among themselves or condensed with a common carbocyclic ring or ring system, with or without other non-condensed hetero rings

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Molecular Biology (AREA)
  • Rheumatology (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Biochemistry (AREA)
  • Pulmonology (AREA)
  • Endocrinology (AREA)
  • Pain & Pain Management (AREA)
  • Diabetes (AREA)
  • Immunology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
AU47106/99A 1998-06-30 1999-06-23 Bicyclic sPLA2 inhibitors Abandoned AU4710699A (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US9124898P 1998-06-30 1998-06-30
US60091248 1998-06-30
PCT/US1999/014213 WO2000000201A1 (en) 1998-06-30 1999-06-23 BICYCLIC sPLA2 INHIBITORS

Publications (1)

Publication Number Publication Date
AU4710699A true AU4710699A (en) 2000-01-17

Family

ID=22226793

Family Applications (1)

Application Number Title Priority Date Filing Date
AU47106/99A Abandoned AU4710699A (en) 1998-06-30 1999-06-23 Bicyclic sPLA2 inhibitors

Country Status (8)

Country Link
US (1) US6384041B1 (enExample)
EP (1) EP1091738B1 (enExample)
JP (1) JP2002519325A (enExample)
AT (1) ATE347362T1 (enExample)
AU (1) AU4710699A (enExample)
CA (1) CA2335448A1 (enExample)
DE (1) DE69934311D1 (enExample)
WO (1) WO2000000201A1 (enExample)

Families Citing this family (23)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2002000621A1 (en) * 2000-06-29 2002-01-03 Shionogi & Co., Ltd. Compounds exhibiting x-type spla2 inhibiting effect
WO2002012249A2 (en) * 2000-08-04 2002-02-14 Eli Lilly And Company Substituted pyrrole compounds and their use as spla2 inhibitors
US6730694B1 (en) 2001-07-20 2004-05-04 Eli Lilly And Company sPLA2 inhibitors
GB0121033D0 (en) * 2001-08-30 2001-10-24 Novartis Ag Organic compounds
AUPS282602A0 (en) 2002-06-07 2002-06-27 Garvan Institute Of Medical Research Method of inhibiting cell proliferation
AR043692A1 (es) * 2003-02-06 2005-08-10 Novartis Ag 2-cianopirrolopirimidinas y sus usos farmaceuticos
US20050124623A1 (en) 2003-11-26 2005-06-09 Bender John A. Diazaindole-dicarbonyl-piperazinyl antiviral agents
US20060100432A1 (en) 2004-11-09 2006-05-11 Matiskella John D Crystalline materials of 1-(4-benzoyl-piperazin-1-yl)-2-[4-methoxy-7-(3-methyl-[1,2,4]triazol-1-yl)-1H-pyrrolo[2,3-c]pyridin-3-yl]-ethane-1,2-dione
US7851476B2 (en) 2005-12-14 2010-12-14 Bristol-Myers Squibb Company Crystalline forms of 1-benzoyl-4-[2-[4-methoxy-7-(3-methyl-1H-1,2,4-triazol-1-YL)-1-[(phosphonooxy)methyl]-1H-pyrrolo[2,3-C]pyridin-3-YL]-1,2-dioxoethyl]-piperazine
US7807671B2 (en) 2006-04-25 2010-10-05 Bristol-Myers Squibb Company Diketo-piperazine and piperidine derivatives as antiviral agents
EP4008327A1 (en) 2009-04-29 2022-06-08 Amarin Pharmaceuticals Ireland Limited Pharmaceutical compositions comprising epa and a cardiovascular agent and methods of using the same
WO2014033208A1 (en) 2012-08-30 2014-03-06 Qiagen Gmbh A method for obtaining blood plasma from a whole blood sample
DE102012215957A1 (de) 2012-09-10 2014-05-15 Schaeffler Technologies Gmbh & Co. Kg Resolverlager
DE102012023252B4 (de) 2012-11-29 2016-11-10 Selux Ag Leuchte mit Elektroladestation für Elektrofahrzeuge
DE102013101611B3 (de) 2013-02-19 2014-07-10 HvS-Consulting AG Verschlüsselungsverfahren für e-mails
DE102013022275A1 (de) 2013-03-28 2014-10-02 Elmos Semiconductor Ag Straßenbeleuchtung
CN103204857A (zh) * 2013-05-08 2013-07-17 兰州聚成生物科技有限公司 一种4-氯-2-(甲硫基)-7h-吡咯并[2,3-d]嘧啶的合成方法
DE102013215468A1 (de) 2013-08-06 2015-02-12 Schaeffler Technologies Gmbh & Co. Kg Tauchlageranordnung und Verfahren zur Abdichtung derselben
EP2902692B1 (de) 2013-12-06 2017-10-25 MAGNA STEYR Engineering AG & Co KG Bauteil eines Tanksystems
US20170033433A1 (en) 2014-04-14 2017-02-02 Shanghai Amphenol Airwave Communication Electronics Co., Ltd. Windshield Antenna
EP3396430B1 (en) 2017-04-27 2023-08-16 Euroimmun Medizinische Labordiagnostika AG Optical scanning arrangement and method
WO2019050890A1 (en) * 2017-09-05 2019-03-14 President And Fellows Of Harvard College METHODS AND COMPOSITIONS FOR THE TREATMENT OF TUBERCULOSIS
CN107915738B (zh) * 2017-11-14 2019-07-26 海化生命(厦门)科技有限公司 用于合成巴瑞替尼的关键中间体2的制备方法

Family Cites Families (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3867386A (en) * 1969-11-04 1975-02-18 American Home Prod 5-amino-2,6-substituted-7h-pyrrolo(2,3-d)pyrimidines and related compounds
US5916922A (en) * 1996-12-03 1999-06-29 Eli Lilly And Company Phenyl glyoxamides as SPLA2 inhibitors

Also Published As

Publication number Publication date
JP2002519325A (ja) 2002-07-02
US6384041B1 (en) 2002-05-07
EP1091738B1 (en) 2006-12-06
EP1091738A1 (en) 2001-04-18
WO2000000201A1 (en) 2000-01-06
DE69934311D1 (de) 2007-01-18
ATE347362T1 (de) 2006-12-15
CA2335448A1 (en) 2000-01-06
EP1091738A4 (en) 2003-03-05

Similar Documents

Publication Publication Date Title
AU4710699A (en) Bicyclic sPLA2 inhibitors
AU5598398A (en) Pyrroles as sPLA2 inhibitors
EP0950657A3 (en) Substituted carbazoles, process for their preparation and their use as sPLA2 inhibitors
AU1621795A (en) 1H-indole-3-glyoxylamide sPLA2 inhibitors
AU3145995A (en) Indolizine spla2 inhibitors
WO2000012504A3 (de) Dihydro-[1,2,3]triazolo-[4,5-d]pyrimidin-7-on
AU7622000A (en) Compounds for the treatment of viral-mediated diseases
WO2002050030A8 (en) Cycloalkylfused [g]-indole compounds as spla2-inhibitors in the treatment of inflammatory diseases
AU7520898A (en) Tetrahydropyrido compounds
AU5833200A (en) Process for the isolation of polymer fractions
EP1100492A4 (en) SPLA 2 INHIBITORS? INDOLE TYPE
AU5454498A (en) Phenyl glyoxamides as spla2 inhibitors
WO2002076396A3 (en) Compounds useful as kinase inhibitors for the treatment of hyperproliferative diseases
DE60022095D1 (en) Camptothecin-beta-alanin-ester mit topoisomerase i hemmung
AU2002227895A1 (en) Sulphonamides for the treatment of central nervous system diseases
AU5873400A (en) spla2 inhibitors
AU1928800A (en) Substituted tricyclics
WO2002012249A3 (en) Substituted pyrrole compounds and their use as spla2 inhibitors
AU2001271611A1 (en) Oxindole derivatives
AU7053700A (en) Novel spla2 inhibitors
AU2003300551A1 (en) Compounds for the inhibition of non-proteolytic enzymes
WO2002050028A3 (en) Substituted benzoindoles as spla2 inhibitors
WO2001030752A3 (en) Indole compounds for treating bacterial infections
WO2001049662A3 (en) Carbazole derivatives as inhibitors of spla2
AU5454600A (en) Process for the isolation of rufomycin factors

Legal Events

Date Code Title Description
MK6 Application lapsed section 142(2)(f)/reg. 8.3(3) - pct applic. not entering national phase